Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata.
作者信息
Seyed Jafari S Morteza, De Viragh Pierre A
机构信息
Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.
出版信息
Acta Derm Venereol. 2025 Aug 12;105:adv44193. doi: 10.2340/actadv.v105.44193.
Abstract
摘要
相似文献
1
Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata.斑秃中对JAK抑制剂反应欠佳的管理策略
Acta Derm Venereol. 2025 Aug 12;105:adv44193. doi: 10.2340/actadv.v105.44193.
2
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
3
The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.JAK 抑制剂治疗斑秃的疗效和安全性评价：2018 例患者的系统评价和荟萃分析。
Front Immunol. 2023 Jun 2;14:1195858. doi: 10.3389/fimmu.2023.1195858. eCollection 2023.
4
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.不同 JAK 抑制剂治疗斑秃的疗效和安全性：网状荟萃分析。
Front Immunol. 2023 Apr 17;14:1152513. doi: 10.3389/fimmu.2023.1152513. eCollection 2023.
5
Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.Janus 激酶抑制剂治疗斑秃：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jun 1;6(6):e2320351. doi: 10.1001/jamanetworkopen.2023.20351.
6
Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis.托法替布治疗儿童斑秃的疗效和安全性：一项系统评价和荟萃分析。
J Cosmet Dermatol. 2022 Dec;21(12):6644-6652. doi: 10.1111/jocd.15425. Epub 2022 Oct 24.
7
Therapeutic management in paediatric alopecia areata: A systematic review.儿童斑秃的治疗管理：系统评价。
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1299-1308. doi: 10.1111/jdv.17187.
8
Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata.托法替布治疗斑秃后复发的治疗策略考量
J Cosmet Dermatol. 2025 Jul;24(7):e70234. doi: 10.1111/jocd.70234.
9
Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata.斑秃对 JAK 抑制剂反应不足的预测因素和管理。
Am J Clin Dermatol. 2024 Nov;25(6):975-986. doi: 10.1007/s40257-024-00884-x. Epub 2024 Sep 3.
10
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.口服酪氨酸激酶3/肝细胞癌中表达的酪氨酸激酶家族激酶抑制剂芦可替尼24个月的疗效和安全性：斑秃的ALLEGRO IIb/III期和长期III期临床研究的综合分析
Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365.
本文引用的文献
1
Combination oral minoxidil and baricitinib treatment of alopecia areata.
J Am Acad Dermatol. 2025 Oct;93(4):1071-1073. doi: 10.1016/j.jaad.2025.05.1393. Epub 2025 May 16.
2
The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis.米诺地尔在斑秃治疗中的作用：一项系统评价和荟萃分析。
J Clin Med. 2024 Dec 17;13(24):7712. doi: 10.3390/jcm13247712.
3
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.斑秃患者巴瑞替尼的长期疗效和安全性：BRAVE-AA1 和 BRAVE-AA2 的 104 周结果。
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):583-593. doi: 10.1111/jdv.19665.
4
European expert consensus statement on the systemic treatment of alopecia areata.欧洲斑秃系统性治疗专家共识声明。
J Eur Acad Dermatol Venereol. 2024 Apr;38(4):687-694. doi: 10.1111/jdv.19768. Epub 2024 Jan 2.
5
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.在接受巴瑞替尼治疗严重斑秃期间何时可以期待头发生长：两项 III 期临床试验中患者轨迹分析的结果。
Br J Dermatol. 2023 Nov 16;189(6):666-673. doi: 10.1093/bjd/ljad253.
6
Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response.斑秃中托法替布和巴瑞替尼之间的转换：临床反应综述
J Am Acad Dermatol. 2023 Dec;89(6):1248-1250. doi: 10.1016/j.jaad.2023.03.041. Epub 2023 Apr 5.
7
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).两项 III 期临床试验（BRAVE-AA1 和 BRAVE-AA2）中连续治疗 52 周时巴瑞替尼治疗严重斑秃患者的疗效和安全性。
Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1.
8
The Role of Micronutrients in Alopecia Areata: A Review.微量元素在斑秃中的作用：综述。
Am J Clin Dermatol. 2017 Oct;18(5):663-679. doi: 10.1007/s40257-017-0285-x.
Zotero 插件